Thanks to a first round of fund raising realized successfully ( 1 500 000€), involving 52 investors, we were able to advance our programs significantly.

We so wish to enter the regulatory preclinical phase , preliminary and critical phase before tests on patients. Once this finished phase ( 2015-2016 ), we shall already have good guarantees that our 2 programs can be acquired by big pharmaceutical groups, having the means to offer not only a return on investment but also to lead the development project until its term.